Advertisement
Table 1 Patient characteristics
| Characteristics* | Phase I (n = 14) | Phase II (n = 49) |
|---|---|---|
| Eligible | 14 (100%) | 45 (92%) |
| Evaluable | 11 (79%) | 36 (73%) |
| Median age (range) years | 59.0 (30.0–69.0) | 63.0 (37.0–71.0) |
| Sex | ||
| Male | 7 (50%) | 33 (67%) |
| Female | 7 (50%) | 16 (33%) |
| WHO performance status | ||
| 0 | 4 (29%) | 14 (29%) |
| 1 | 10 (71%) | 31 (63%) |
| 2 | 0 | 4 (8%) |
| Primary tumour site | ||
| Colon | 9 (64%) | 17 (35%) |
| Rectum | 4 (29%) | 22 (45%) |
| Colon rectosigmoid | 1 (7%) | 10 (20%) |
| Organ involved | ||
| Median number | 2 (1–4) | 2 (1–4) |
| Liver | 10 (71%) | 42 (86%) |
| Lung | 6 (43%) | 17 (35%) |
| Lymph node | 1 (7%) | 10 (20%) |
| Other soft tissue | 0 | 11 (22%) |
| Abdominal cavity | 2 (14%) | 3 (6%) |
| Peritoneum | 1 (7%) | 0 |
| Bone | 1 (7%) | 0 |
| Skin | 0 | 1 (2%) |
| Other | 2 (14%) | 5 (10%) |
| Prior therapy | ||
| Surgery | 12 (86%) | 42 (86%) |
| Radiotherapy | 3 (21%) | 14 (29%) |
| Adjuvant chemotherapy | 4 (29%) | 12 (24%) |
| Surgery + radiotherapy | 3 (21%) | 12 (24%) |
| Surgery + chemotherapy | 4 (29%) | 12 (24%) |
| Radiotherapy + chemotherapy | 2 (14%) | 7 (14%) |
| Surgery + radiotherapy + chemotherapy | 2 (14%) | 7 (14%) |
